united states senate novo nordisk news - Search News

Ozempic CEO in hot seat in Senate hearing

The Washington Post · 2d

Senators press Novo Nordisk CEO on why Ozempic and Wegovy cost less abroad

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for brand-name prescriptions.

Hosted on MSN · 2d

Novo Nordisk's CEO took the Washington hot seat over Ozempic prices. 3 takeaways from his testimony

CEO Lars Fruergaard Jørgensen agreed today, during a Senate committee hearing, to sit down with lawmakers and pharmacy benefit managers (PBMs) to look into the possibility of cutting list prices for the company’s popular diabetes and weight-loss drugs.

Benzinga.com · 3d

Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday

Novo Nordisk CEO Lars Fruergaard Jørgensen faces a Senate hearing led by Bernie Sanders over the high cost of Ozempic and Wegovy, as U.S. lawmakers push for drug price reductions.

1don MSN

Senate panel questions Novo Nordisk CEO over decision to discontinue this popular insulin

Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health ...

2d

Novo Nordisk CEO grilled over steep weight loss drug costs

Novo Nordisk CEO Lars Fruergaard Jørgensen testified before the Senate Health, Education, Labor and Pension committee on ...

2d

US Congress calls on Novo Nordisk to lower drug prices

The boss of the Danish pharmaceutical giant behind the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy promised ...

2d

Why does Ozempic cost so much? Senators grilled Novo Nordisk CEO for answers.

Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.

Braun to Novo Nordisk CEO: “Why are Americans paying more for the same drug?”

WASHINGTON—U.S. Senator Mike Braun questioned Novo Nordisk CEO, Lars Fruergaard Jørgensen, at the Senate Health, Education, ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results